The novel first-line therapy for rett syndrome

  • Authors

    • Wania Sultan Dow University of Heath and Sciences
    • Hamza Irfan Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore
    • Kainat Shariq DOW UNIVERSITY OF HEALTH SCIENCES (DUHS)
    2023-10-12
    https://doi.org/10.14419/zpn3s949

  • Rett Syndrome (RTT) is a neurodevelopmental disorder predominantly affecting females and characterized by hyperkinetic movement disorders and related symptoms. At present, the available treatments for RTT primarily focus on managing symptoms and providing supportive care. This article examines the emergence of trofinetide as an innovative therapeutic approach targeting the underlying molecular and synaptic abnormalities associated with RTT. The approval of trofinetide, marketed as DAYBUE™, as the primary treatment for Rett Syndrome by the US Food and Drug Administration (FDA) is based on encouraging outcomes from clinical trials. Ongoing open-label studies are currently underway to evaluate the long-term efficacy and safety of trofinetide in various age groups, thus providing valuable insights into its sustained benefits. These advancements in research, along with other potential treatments under investigation, offer promising prospects for the development of improved and personalized management strategies for individuals with Rett Syndrome.

  • References

    1. S. Brunetti and D. E. Lumsden, “Rett Syndrome as a movement and motor disorder – A narrative review,” Eur. J. Paediatr. Neurol., vol. 28, pp. 29–37, Sep. 2020, https://doi.org/10.1016/j.ejpn.2020.06.020.
    2. C. Fu et al., “Original research: Consensus guidelines on managing Rett syndrome across the lifespan,” BMJ Paediatr. Open, vol. 4, no. 1, p. 717, Jan. 2020, https://doi.org/10.1136/bmjpo-2020-000717.
    3. FDA, “FDA approves first treatment for Rett Syndrome | FDA.” https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-rett-syndrome (accessed May 06, 2023).
    4. H. H. Wei et al., “NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats,” J. Neuroinflammation, vol. 6, p. 19, Aug. 2009, https://doi.org/10.1186/1742-2094-6-19.
    5. J. L. Neul et al., “Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome,” Contemp. Clin. Trials, vol. 114, p. 106704, Mar. 2022, https://doi.org/10.1016/j.cct.2022.106704.
    6. D. G. Glaze et al., “A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome,” Pediatr. Neurol., vol. 76, pp. 37–46, Nov. 2017, https://doi.org/10.1016/j.pediatrneurol.2017.07.002.
    7. D. G. Glaze et al., “Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome,” Neurology, vol. 92, no. 16, p. e1912, Apr. 2019, https://doi.org/10.1212/WNL.0000000000007316.
    8. Fda and Cder, “HIGHLIGHTS OF PRESCRIBING INFORMATION”, Accessed: Jun. 14, 2023. [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217026s000lbl.pdf
    9. A. Djukic et al., “OP23 – 2759: Pharmacological treatment of Rett syndrome with glatiramer acetate (Copaxone),” Eur. J. Paediatr. Neurol., vol. 19, p. S8, May 2015, https://doi.org/10.1016/S1090-3798(15)30024-6.
    10. “Tolerability of the Immersive Virtual Reality System Grail in Subjects Affected by Rett Syndrome - Full Text View - ClinicalTrials.gov.” https://clinicaltrials.gov/ct2/show/NCT05691582?cond=Rett+Syndrome&draw=2&rank=1 (accessed Jun. 14, 2023).

  • Downloads

  • How to Cite

    Sultan, W., Irfan, H., & Shariq, K. (2023). The novel first-line therapy for rett syndrome. International Journal of Medicine, 11(1), 15-16. https://doi.org/10.14419/zpn3s949